Long-term outcome of cord blood transplantation from unrelated donors as an initial transplantation procedure for children with AML in Japan

Bone Marrow Transplantation

Volumn 45, Issue 1, 2010, Pages 69-77

  Isoyama, K ^a,b   Oda, M ^c,d   Kato, K ^e,f   Nagamura Inoue, T ^g,h   Kai, S ^i,j   Kigasawa, H ^k   Kobayashi, R ^l   Mimaya, J ^m   Inoue, M ⁿ   Kikuchi, A ^o   Kato, S ^p,q  

^a SHOWA UNIVERSITY FUJIGAOKA HOSPITAL   (Japan)

^b Kanagawa Cord Blood Bank   (Japan)

^c Chugoku Shikoku Cord Blood Bank   (Japan)

^d OKAYAMA UNIVERSITY   (Japan)

^e JAPANESE RED CROSS NAGOYA FIRST HOSPITAL   (Japan)

^f Tokai Cord Blood Bank   (Japan)

^g UNIVERSITY OF TOKYO   (Japan)

^h Tokyo Cord Blood Bank   (Japan)

ⁱ HYOGO COLLEGE OF MEDICINE   (Japan)

^j Hyogo College of Medicine   (Japan)

^k KANAGAWA CHILDREN'S MEDICAL CENTER   (Japan)

^l SAPPORO HOKUYU HOSPITAL   (Japan)

^m SHIZUOKA CHILDREN'S HOSPITAL   (Japan)

ⁿ RESEARCH INSTITUTE FOR MATERNAL AND CHILD HEALTH   (Japan)

^o SAITAMA CHILDREN'S MEDICAL CENTER   (Japan)

^p TOKAI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^q TOKAI UNIVERSITY   (Japan)

more..

Author keywords

AML; Children; Cord blood transplantation

Indexed keywords

CYCLOSPORIN A; GRANULOCYTE COLONY STIMULATING FACTOR; HEMOPOIETIC GROWTH FACTOR; METHOTREXATE; TACROLIMUS;

ACUTE GRAFT VERSUS HOST DISEASE; ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ARTICLE; CANCER STAGING; CD34 SELECTION; CHEMOPROPHYLAXIS; CHILD; CORD BLOOD STEM CELL TRANSPLANTATION; DISEASE ACTIVITY; DISEASE SEVERITY; DONOR SELECTION; FEMALE; FOLLOW UP; HUMAN; INCIDENCE; JAPAN; KARYOTYPE; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MORTALITY; MYELOABLATIVE CONDITIONING; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; RECURRENCE RISK; RETROSPECTIVE STUDY; SHORT COURSE THERAPY; SURVIVAL TIME; TREATMENT RESPONSE; UMBILICAL CORD BLOOD; WHOLE BODY RADIATION;

ADOLESCENT; ANTIGENS, CD34; CHILD; CHILD, PRESCHOOL; CORD BLOOD STEM CELL TRANSPLANTATION; FEMALE; GRAFT SURVIVAL; GRAFT VS HOST DISEASE; HUMANS; INFANT; JAPAN; LEUKEMIA, MYELOID, ACUTE; LEUKOCYTE COUNT; MALE; NEOPLASM RECURRENCE, LOCAL; NEUTROPHILS; PLATELET COUNT; RETROSPECTIVE STUDIES; TISSUE DONORS; TRANSPLANTATION CONDITIONING; TREATMENT OUTCOME;

EID: 75149193159     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2009.93     Document Type: Article

References (36)

1. Gibson BES, Wheatley K, Hann IM, Stevens RF, Webb D, Hills RK, et al.., De Graaf SSN and Harrison CJ for the United Kingdom. Childhood Leukaemia Working Party, and the Dutch Childhood Oncology Group. Treatment strategy and long-term results in paediatric patients treated in consecutive UK AML trials. Leukemia 2005; 19: 2130-2138.
2. Creutzig U, Zimmermann M, Ritter J, Reinhardt D, Hermann J, Henze G et al.. Treatment strategies and long-term results in paediatric patients treated in four consecutive AML-BFM trials. Leukemia 2005; 19: 2030-2042.
3. Smith FO, Alonzo TA, Gerbing RB, Woods WG, Arceci RJ. Long-term results of children with acute myeloid leukemia: a report of three consecutive Phase III trials by the Children's Cancer Group: CCG 251, CCG 213 and CCG 2891. Leukemia 2005; 19: 2054-2062.
4. Ravindranath Y, Chang M, Steuber CP, Becton D, Dahl G, Civin C et al.. Pediatric Oncology Group (POG) studies of acute myeloid leukemia (AML): a review of four consecutive childhood AML trials conducted between 1981 and 2000. Leukemia 2005; 19: 2101-2116.
5. Aladjidi N, Auvrignon A, Leblanc T, Perel Y, Bénard A, Bordigoni P et al.. Outcome in children with relapsed acute myeloid leukemia after initial treatment with the French Leucemie Aique Myeloide Enfant (LAME) 89/91 protocol of the French Society of Pediatric Hematology and Immunology. J Clin Oncol 2003; 21: 4377-4385.
6. Abrahamsson J, Clausen N, Gustafsson G, Hovi L, Jonmundsson G, Zeller B et al.. Nordic Society for Paediatric Haematology and Oncology (NOPHO). Improved outcome after relapse in children with acute myeloid leukaemia. Br J Haematol 2007; 136: 229-236.
7. Johnston DL, Alonzo TA, Gerbing RB, Lange BJ, Woods WG. Risk factors and therapy for isolated central nervous system relapse of pediatric acute myeloid leukemia. J Clin Oncol 2005; 23: 9172-9178.
8. Rubnitz JE, Razzouk BI, Lensing S, Pounds S, Pui CH, Ribeiro RC. Prognostic factors and outcome of recurrence in childhood acute myeloid leukemia. Cancer 2007; 109: 157-163.
9. Balduzzi A, Gooley T, Anasetti C, Sanders JE, Martin PJ, Petersdorf EW et al.. Unrelated donor marrow transplantation in children. Blood 1995; 86: 3247-3256.
10. Sierra J, Storer B, Hansen JA, Martin PJ, Petersdorf EW, Woolfrey A et al.. Unrelated donor marrow transplantation for acute myeloid leukemia: an update of the Seattle experience. Bone Marrow Transplant 2000; 26: 397-404. (Pubitemid 30649555)
11. Marks DI, Bird JM, Vettenranta K, Hunt L, Green A, Cornish JM et al.. T cell-depleted unrelated donor bone marrow transplantation for acute myeloid leukemia. Biol Blood Marrow Transplant 2000; 6: 646-653.
12. Kurtzberg J, Laughlin M, Graham ML, Smith C, Olson JF, Halperin EC et al.. Placental blood as a source of hematopoietic stem cells for transplantation in unrelated recipients. N Engl J Med 1996; 335: 157-166.
13. Wagner JE, Rosenthal J, Sweetman R, Shu XO, Davies SM, Ramsay NK et al.. Successful transplantation of HLA-matched and HLA-mismatched umbilical cord blood from unrelated donors: analysis of engraftment and acute graft-versus-hostdisease. Blood 1996; 88: 795-802.
14. Gluckman E, Rocha V, Boyer-Chammard A, Locatelli F, Arcese W, Pasquini R et al.. Outcome of cord-blood transplantation from related and unrelated donors. Eurocord Transplant Group and the European Blood and Marrow Transplantation Group. N Engl J Med 1997; 337: 373-381.
15. Rubinstein P, Carrier C, Scaradavou A, Kurtzberg J, Adamson J, Migliaccio AR et al.. Outcome among 562 recipients of placental blood transplants from unrelated donors. N Engl J Med 1998; 339: 1565-1577.
16. Rocha V, Cornish J, Sievers EL, Filipovich A, Locatelli F, Peters C et al.. Comparison of outcome of unrelated bone marrow and umbilical cord blood transplants in children with acute leukemia. Blood 2001; 97: 2962-2971.
17. Ohnuma K, Isoyama K, Ikuta K, Toyoda Y, Nakamura J, Nakajima F et al.. Cord blood transplantation from HLAmismatched unrelated donors as a treatment for children with haematological malignancies. Br J Haematol 2001; 112: 981-987.
18. Isoyama K, Ohnuma K, Kato K, Takahashi TA, Kai S, Kato S, et al.., Japanese Cord Blood Bank Network. Cord blood transplantation from unrelated donors: a preliminary report from the Japanese Cord Blood Bank Network. Leuk Lymphoma 2003; 44: 429-438.
19. Michel G, Rocha V, Chevret S, Arcese W, Chan KW, Filipovich A et al.. Unrelated cord blood transplantation for childhood acute myeloid leukemia: a Eurocord Group analysis. Blood 2003; 102: 4290-4297.
20. Gluckman E, Rocha V, Arcese W, Michel G, Sanz G, Chan KW, et al.., Eurocord Group. Factors associated with outcomes of unrelated cord blood transplant: guidelines for donor choice. Exp Hematol 2004; 32: 397-407.
21. Wall DA, Carter SL, Kernan NA, Kapoor N, Kamani NR, Brochstein JA, et al.., COBLT Steering Committee. Busulfan/ melphalan/antithymocyte globulin followed by unrelated donor cord blood transplantation for treatment of infant leukemia and leukemia in young children: the Cord Blood Transplantation study (COBLT) experience. Biol Blood Marrow Transplant 2005; 11: 637-646.
22. Sobocinski KA, Horowitz MM, Rowlings PA, Zhang MJ, Nugent ML, Passweg JR et al.. Bone marrow transplantation- 1994: a report from the International Bone Marrow Transplant Registry and the North American Autologous Bone Marrow Transplant Registry. J Hematother 1994; 3: 95-102.
23. Moretti S, Dabusti M, Castagnari B, Tieghi A, Ferrari L, Campioni D et al.. Comparison of single and dual platform methodologies for the estimation of CD34+ hematopoietic progenitor cells: correlation with colony assay. Int J Biol Markers. 2002; 17: 259-267.
24. Glucksberg H, Storb R, Fefer A, Buckner CD, Neiman PE, Clift RA et al.. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation 1974; 18: 295-304.
25. Storb R, Prentice RL, Sullivan KM, Shulman HM, Deeg HJ, Doney KC et al.. Predictive factors in chronic graft-versus-host disease in patients with aplastic anemia treated by marrow transplantation from HLA-identical siblings. Ann Intern Med 1983; 98: 461-466.
26. Gooley TA, Leisenring W, Crowley J, Storer BE. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med 1999; 18: 695-706.
27. Fine JP, Gray RJ. A proportional hazards model for the sub distribution of a competing risk. J Am Stat Assoc 1999; 94: 496-509.
28. Grimwade D, Walker H, Oliver F, Wheatley K, Harrison C, Harrison G et al.. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. Blood 1998; 92: 2322-2333.
29. Klingebiela T, Handgretingerb R, Langc P, Baderc Peter, Niethammerc D. Haploidentical transplantation for acute lymphoblastic leukemia in childhood. Blood Rev 2004; 18: 181-192.
30. Locatelli F, Rocha V, Chastang C, Arcese W, Michel G, Abecasis M, et al.., for Eurocord-Cord Blood Transplant Group. Factors associated with outcome after cord blood transplantation in children with acute leukemia. Blood 1999; 93: 3662-3671.
31. Barker JN, Davies SM, DeFor T, Ramsay NK, Weisdorf DJ, Wagner JE. Survival after transplantation of unrelated donor umbilical cord blood is comparable to that of HLA-matched unrelated donor bone marrow: results of a matched-pair analysis. Blood 2001; 97: 2957-2961.
32. Storb R, Deeg HJ, Pepe M, Appelbaum F, Anasetti C, Beatty P et al.. Methotrexate and cyclosporine versus cyclosporine alone for prophylaxis of graft-versus-host disease in patients given HLA-identical marrow grafts for leukemia: long-term follow-up of a controlled trial. Blood 1989; 73: 1729-1734. (Pubitemid 19131924)
33. Przepiorka D, Ippoliti C, Khouri I, Woo M, Mehra R, Le Bherz D et al.. Tacrolimus and minidose methotrexate for prevention of acute graft-versus-host disease after matched unrelated donor marrow transplantation. Blood 1996; 88: 4383-4389.
34. Narimatsu H, Terakura S, Matsuo K, Oba T, Uchida T, Iida H et al.. Short-term methotrexate could reduce early immune reactions and improve outcomes in umbilical cord blood transplantation for adults. Bone Marrow Transplant 2007; 39: 31-39.
35. Wagner JE, Barker JN, DeFor TE, Baker KS, Blazar BR, Eide C et al.. Transplantation of unrelated donor umbilical cord blood in 102 patients with malignant and non-malignant diseases: influence of CD34 cell dose and HLA disparity on treatment-related mortality and survival. Blood 2002; 100: 1611-1618.
36. Webb DKH, Weatley K, Harrison G, Stevens RF, Hann IM. Outcome for children with relapsed acute myeloid leukaemia following initial therapy in the Medical Research Council (MRC) AML 10 trial. MRC Childhood Leukaemia Working Party. Leukemia 1999; 13: 25-31.